Cardiac Ganglionated Plexus Ablation Before Permanent Pacemaker Implantation in Patients With Sick Sinus Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-28

Study Completion Date

2021-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Different studies for cardiac ganglionated plexus（GP） ablation to treat vagal vascular syncope, sinus node dysfunction, and functional atrioventricular block have been published. Investigators have developed a more specific approach of cardiac, called cardioneuroablation . This treatment is based on a high-frequency stimulation (HFS) and/or anatomical landmarks to identify GPs in left atrium，which being targeted by radiofrequency catheter ablation. The feasibility of GPs ablation/cardioneuroablation has already been tested in our center in former studies in humans,with a favorable outcome for the patients involved. The results of the former studies have been submitted for publication. However, there are no prospective randomized studies to evaluate the efficacy and safety of atrial ganglionated plexus ablation for SSS before permanent pacemaker implantation.

The purpose of this study of GAPS in humans is to evaluate the efficacy and safety of cardioneuroablation in patients of sick sinus syndrome before they receive a permanent pacemaker.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia

NCT05820035

Paroxysmal Supraventricular Tachycardia Atrioventricular Nodal Reentrant Tachycardia Atrioventricular Reciprocating Tachycardia

COMPLETED NA

Prospective Evaluation of CT Guided Ablation of Cardiac Ganglionated Plexi

NCT04642976

Atrial Fibrillation

COMPLETED

Ganglionated Plexus Ablation For Treatment of Atrial Fibrillation

NCT02267889

Atrial Fibrillation

COMPLETED NA

Additional Low Voltage Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation

NCT03462628

Paroxysmal Atrial Fibrillation

COMPLETED NA

Wide Area Circumferential Ablation With Contact Force Versus Cryoballoon Ablation

NCT03564925

Atrial Fibrillation CryoAblation Pulmonary Vein Isolation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter,prospective, open, interventional study. All patients will undergo permanent pacemaker implantation. The study will involve eight different steps, from the screening procedure through study completion: screening, enrollment, pharmacological testing, randomization of group allocation, preprocedural assessment, procedure, follow-up, study completion. The dedicated study members (cardiac electrophysiologists, statisticians) and the PI are responsible for recording all data from the trial on the case report forms (CRFs) and completing the study database. The participants will be randomly allocated in a 1:1 ratio to either GPs ablation followed by permanent pacemaker implantation or pacemaker alone. Randomization will be conducted centrally by an independent statistics department(Oxford Medical Center of National Center for Cardiovascular Diseases, Beijing, China) and stratified by center and age(\<50 or \>=50 years); A dedicated independent physician will be responsible for the safety monitoring. The PI will permit inspection of the trial files and the database by national or international official controlling scientific authorities, if required. The PI will review and monitor completed CRFs and the database at regular intervals throughout the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardioneuroablation Permanent Pacemaker Implantation Sick Sinus Syndrome Ganglionated Plexus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ablation group(Ablation+pacemaker)

The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.

After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group).

Group Type EXPERIMENTAL

cardiac ganglion plexus ablation(cardioneuroablation)

Intervention Type PROCEDURE

Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.

Permanent pacemaker implantation

Intervention Type DEVICE

DDD permanent pacemaker will be implanted in the paticipants.

Control group(only pacemaker)

The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.

Group Type SHAM_COMPARATOR

Permanent pacemaker implantation

Intervention Type DEVICE

DDD permanent pacemaker will be implanted in the paticipants.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac ganglion plexus ablation(cardioneuroablation)

Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.

Intervention Type PROCEDURE

Permanent pacemaker implantation

DDD permanent pacemaker will be implanted in the paticipants.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

St. Jude Medical or Medtronic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sign the informed consent form.
* Diagnosed as SSS, with recurrent symptomatic bradycardia, blackouts, syncope, etc.
* Meet the indications for permanent pacemaker implantation according to the 2018 Chinese pacemaker guidelines (Class I, Class IIa).
* Positive reaction to atropine: The PP interval shortened by more than 20% or the sinus heart rate\>60 bpm after intravenous injection of 2 mg of atropine.

Exclusion Criteria

* Age \<14 years old or \>75 years old.
* Accompanied with complex congenital heart disease, valvular heart disease, cardiomyopathy and other chronic diseases, such as heart failure (NYHA grade III or IV).
* Acute coronary syndrome or myocardial infarction occurred within 6 months. Cerebrovascular events (such as transient ischemic attack, stroke) or other cerebral blood supply disorders occurred within 3 months.
* History of cardiac surgery and/or permanent cardiac pacemaker implantation.
* TEE or CT found a left atrial thrombus and/or left atrial anteroposterior diameter \> 55mm or LVEF \< 35%.
* Persistent atrial fibrillation, high-degree or complete atrioventricular block; double or triple fascicular block.

Minimum Eligible Age

14 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No